Aquestive Therapeutics, Inc. - Common Stock (AQST)

Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review.

Aquestive's Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025.

Stocktwits users are viewing the company's cash position, expectations for a late 2026 Anaphylm launch, and an upcoming trial as positive signals.

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside.

Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC Wainwright raises its price target amid promising developments.

Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic reactions.

AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

U.S. stocks were higher, with the Dow Jones gaining over 150 points on Thursday.

U.S. stocks traded higher toward the end of trading, after the Federal Reserve left rates unchanged. The Dow traded up 0.91% to 39,467.76 while the NASDAQ rose 1.08% to 16,341.42. The S&P 500 also rose, gaining, 0.78% to 5,218.70.

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.